Gilead Sciences Inks $247M Deal For HIV Antitrust Claims

By Matthew Perlman · August 10, 2023, 5:32 PM EDT

Gilead has agreed to pay direct purchasers of its HIV medications $246.8 million, ending claims the pharmaceutical company cut a deal with Teva to delay generic versions after reaching an initial...

To view the full article, register now.
Try a seven day FREE Trial

Already a subscriber? Click here to login